Moderate to Severe Chronic Plaque Psoriasis
Conditions
Keywords
Psoriasis, Related to Health Quality of Life, Patient Reported Outcomes, Venezuelan Patients
Brief summary
The aim of this study is to obtain Venezuelan data of clinical effectiveness, impact in the HRQoL, work productivity and activity impairment in patients with psoriasis using adalimumab.
Interventions
None listed
Sponsors
AbbVie (prior sponsor, Abbott)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis, who have the indication for adalimumab because they need systemic therapy or because they have had failure to phototherapy, or to other systemic or topical treatments * Subjects that are not receiving biologic therapy in the last 12 weeks or classical therapy in the past 4 weeks and/or phototherapy in the last 2 weeks. Topical therapy will be allowed, to a constant dose and will not be used within 24 hours prior to the visit * Patients under previous treatment with any experimental drug will have a minimum washout period of five half-lives * Subjects must be capable to understand and willing to give a written informed consent form to release information and to comply with the requirements of the study protocol
Exclusion criteria
* Subjects should not be enrolled if they cannot be treated in accordance with the local product label approved in Venezuela * Subjects enrolled into another study or under treatment with an investigational product * History of viral hepatitis B infection or HIV * History of neurologic symptoms suggestive of central nervous system demyelinating disease * History of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix) * Active TB infection before initiating adalimumab treatment or latent TB infection not able to complete prophylactic treatment * Pregnant or lactating female. Pregnancy will be tested before entering the study in fertile women. Women in fertile age must be advised by the physician, to use a clinically accepted contraceptive method (contraceptive pills, IUDs, barrier devices as condoms or abstinence) * History of congestive heart failure (CHF) * Any another condition that according to the criteria of the participating investigator represents an obstacle for study conduction and / or subjects to an unacceptable risks * Subjects with active infection including chronic or localized infections until infections are controlled * History of sensitive to latex or other component of the syringe * Subjects who requires concomitant phototherapy and systemic therapy during adalimumab therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in PASI 75 (Psoriasis Area and Severity Index score) Response Rate | From Week 0 to Week 16 | — |
| Change in Percentage of patients with clinical difference in DLQI (Dermatology Life Quality Index) score | From Week 0 to Week 16 | Clinical difference is defined by a minimal important difference (MID) in DLQI score between 2.3-5 at 16 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Psoriatic Arthritis Response Criteria (PsARC) score | From week 0 to week 16 | — |
| Mean change of Hospital Anxiety and Depression Score (HADS) | From week 0 to week 16 | — |
| Mean change of PASI score | From week 0 to week 16 | — |
| Percentage of subjects with Serious Adverse Events (SAEs) | Up to week 16 | Occurrence of SAEs including tuberculosis, other opportunistic infections and cancer |
| Discontinuation of adalimumab for any reason. | Up to week 16 | — |
| Mean change en Work Productivity and Activity Impairment (WPAI)-Psoriasis score | From week 0 to week 16 | — |
| Mean change of DLQI score | From week 0 to week 16 | — |
Outcome results
None listed